- Home
- LICN vs THAR Comparison
LICN vs THAR Comparison
Compare LICN & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LICN
- THAR
- Stock Information
- Founded
- LICN 2004
- THAR 2017
- Country
- LICN China
- THAR United States
- Employees
- LICN N/A
- THAR N/A
- Industry
- LICN
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- LICN
- THAR Health Care
- Exchange
- LICN Nasdaq
- THAR Nasdaq
- Market Cap
- LICN 2.1M
- THAR 3.3M
- IPO Year
- LICN 2023
- THAR 2022
- Fundamental
- Price
- LICN $4.92
- THAR $1.45
- Analyst Decision
- LICN
- THAR Strong Buy
- Analyst Count
- LICN 0
- THAR 1
- Target Price
- LICN N/A
- THAR $17.00
- AVG Volume (30 Days)
- LICN 1.7M
- THAR 56.4K
- Earning Date
- LICN 01-01-0001
- THAR 05-12-2025
- Dividend Yield
- LICN N/A
- THAR N/A
- EPS Growth
- LICN N/A
- THAR N/A
- EPS
- LICN N/A
- THAR N/A
- Revenue
- LICN $41,477,000.00
- THAR N/A
- Revenue This Year
- LICN N/A
- THAR N/A
- Revenue Next Year
- LICN N/A
- THAR N/A
- P/E Ratio
- LICN N/A
- THAR N/A
- Revenue Growth
- LICN 4.32
- THAR N/A
- 52 Week Low
- LICN $2.60
- THAR $0.95
- 52 Week High
- LICN $488.00
- THAR $6.39
- Technical
- Relative Strength Index (RSI)
- LICN 49.93
- THAR 52.59
- Support Level
- LICN $5.61
- THAR $1.38
- Resistance Level
- LICN $6.16
- THAR $1.45
- Average True Range (ATR)
- LICN 1.10
- THAR 0.11
- MACD
- LICN -0.11
- THAR -0.00
- Stochastic Oscillator
- LICN 40.85
- THAR 59.88
About LICN Lichen China Limited
Lichen International Ltd formerly Lichen China Ltd is a holding company. The company, along with its subsidiaries provides financial and taxation solution services; education support services; and software and maintenance services. The company generates Majority revenue from Financial and taxation solution services.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.